Valuation : Axonics, Inc.

Market Cap 3.63B 3.12B 2.93B 2.68B 5B 343B 5.04B 34.65B 13.49B 175B 13.62B 13.33B 564B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.85B 2.67B 2.45B 4.56B 313B 4.6B 31.62B 12.31B 160B 12.43B 12.16B 515B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.3
Extreme 48.3
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 69 01/02/2018
Director/Board Member 74 08/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Issuer sale

Executive/Senior Manager

59,355 0.1161%
15/11/24 Issuer sale

Responsable ventes & marketing

109,664 0.2145%
15/11/24 Issuer sale

Chief Technology Officer

63,237 0.1237%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+22.38% 3.63B
-0.48%-7.60%-22.51%+6.73% 118B
+1.07%-0.24%-24.82%+0.47% 11.98B
-2.13%-0.97%+97.60%+142.08% 10.63B
-1.67%-2.75%-51.34%-70.90% 4.09B
+0.91%-9.24%-24.44%+36.04% 2.48B
-0.31%-5.16% - - 1.97B
+0.73%+1.48%-27.77%-73.39% 1.8B
-0.08%-4.78%-19.87%-25.18% 1.56B
Average -0.15%-2.75%-9.14%+4.78% 17.36B
Weighted average by Cap. -0.55%-3.81%-14.72%+13.10%

Financials

2022 2023
Net sales 274M 235M 221M 202M 377M 25.87B 380M 2.61B 1.02B 13.22B 1.03B 1.01B 42.58B 366M 315M 296M 271M 505M 34.63B 509M 3.5B 1.36B 17.7B 1.38B 1.35B 57B
Net income -59.7M -51.36M -48.2M -44.1M -82.31M -5.64B -82.96M -570M -222M -2.88B -224M -219M -9.29B -6.09M -5.24M -4.92M -4.5M -8.39M -576M -8.46M -58.15M -22.65M -294M -22.86M -22.36M -947M
Net Debt -348M -300M -281M -257M -480M -32.91B -484M -3.32B -1.29B -16.82B -1.31B -1.28B -54.16B -317M -273M -256M -234M -438M -30B -441M -3.03B -1.18B -15.33B -1.19B -1.17B -49.37B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock